Prostate specific membrane antigen (PSMA) is highly expressed in prostate cancer (PCa) and, when imaged by targeted PET radioligands, provides a crucial biomarker to assess disease burden with the potential for patient stratification to receive PRRT (Werner et al. 2020; Rahbar et al. 2017; Sathekge et al. 2019). This evidence concerns the gene FOLH1 and prostate cancer.